2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity despite completely different indications.

In both cases, an added benefit is not proven, despite the fact that the active substances showed effects in randomised controlled trials.

The reason: the treatment in the comparative arms of the trials lagged behind today's care standards and do not correspond to the ACT, which was set by the Federal Joint Committee (G-BA) for the respective early benefit assessment.

Read IQWiG press release [German]